Two communications have been made at the AHA 2024 in Chicago on COR-1167 and COR-1389:
- COR-1389: Data presented indicated that our long-acting CRF2 receptor agonist, COR-1389, improved cardiopulmonary function and the adverse maladaptive cardiac remodeling in the rat model of Sugen plus hypoxia-induced pulmonary arterial hypertension and right heart failure.
- COR-1167: In the setting of WHF rat model, COR-1167 administered on top of an SGLT2 inhibitor significantly improved cardiac function, perfusion and energetics as well as natriuresis and diuresis.